Veterinary Medicines Directorate
Woodham Lane, New Haw, Addlestone, Surrey, KT15 3LS
Telephone +44 (0)1932 336911

Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021, please refer to the EMA website.

Vaxxitek HVT+IBD Suspension and Solvent for Suspension for Injection

Vm 04491/5060

•	22 February 2024	G.I.18 update of the product information.
•	10 May 2023	Declaring the addition of Bioluz Laboratory as an alternative manufacturer responsible for the batch release of the solvent used for the resuspension of Vaxxitek HVT+IBD
•	26 April 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
•	27 February 2023	The variation regards the compatibility claim between PREVEXXION RN or PREVEXXION RN+HVT+IBD and VAXXITEK HVT+IBD. The new studies are aimed at demonstrating the absence of interference between the two vaccinal strains RN1250 and vHVT013-69 on Infectious bursal disease protection.
•	08 July 2022	Change in the invented name of the solvent to more general name 'Solvent for cell associated poultry vaccines'.
•	24 June 2022	Deletion of a quality control testing site.
•	22 June 2022	Update of the test procedures to reflect compliance with the Ph. Eur and removal of the reference to the outdated internal test method.
•	24 March 2022	Change to part of the (primary) packaging material not in contact with the finished product formulation.
•	08 March 2022	Change in the manufacturer of a starting material used in the manufacturing process of the active.
•	22 December 2021	Change to in-process tests or limits applied during the manufacture of the finished product.
•	26 March 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	01 March 2021	Change(s) in the SPC, labelling or package leaflet further to a veterinary PSUR